Compare Glenmark Pharma with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs ABBOTT INDIA - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA ABBOTT INDIA GLENMARK PHARMA/
ABBOTT INDIA
 
P/E (TTM) x 11.4 56.1 20.3% View Chart
P/BV x 1.6 13.5 12.0% View Chart
Dividend Yield % 0.6 0.5 121.9%  

Financials

 GLENMARK PHARMA   ABBOTT INDIA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-19
ABBOTT INDIA
Mar-19
GLENMARK PHARMA/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs7128,834 8.1%   
Low Rs4845,458 8.9%   
Sales per share (Unadj.) Rs349.61,731.1 20.2%  
Earnings per share (Unadj.) Rs32.8211.9 15.5%  
Cash flow per share (Unadj.) Rs44.3219.9 20.2%  
Dividends per share (Unadj.) Rs2.0065.00 3.1%  
Dividend yield (eoy) %0.30.9 36.8%  
Book value per share (Unadj.) Rs198.6945.2 21.0%  
Shares outstanding (eoy) m282.1721.25 1,327.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.74.1 41.4%   
Avg P/E ratio x18.233.7 54.1%  
P/CF ratio (eoy) x13.532.5 41.5%  
Price / Book Value ratio x3.07.6 39.8%  
Dividend payout %6.130.7 19.9%   
Avg Mkt Cap Rs m168,625151,848 111.0%   
No. of employees `00012.03.5 345.4%   
Total wages/salary Rs m20,5614,356 472.0%   
Avg. sales/employee Rs Th8,196.010,555.5 77.6%   
Avg. wages/employee Rs Th1,708.11,249.9 136.7%   
Avg. net profit/employee Rs Th768.51,292.2 59.5%   
INCOME DATA
Net Sales Rs m98,65536,786 268.2%  
Other income Rs m2,0811,133 183.7%   
Total revenues Rs m100,73637,919 265.7%   
Gross profit Rs m15,8586,047 262.2%  
Depreciation Rs m3,259169 1,926.2%   
Interest Rs m3,34623 14,870.7%   
Profit before tax Rs m11,3356,989 162.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1,6720-   
Tax Rs m3,7562,485 151.2%   
Profit after tax Rs m9,2504,503 205.4%  
Gross profit margin %16.116.4 97.8%  
Effective tax rate %33.135.6 93.2%   
Net profit margin %9.412.2 76.6%  
BALANCE SHEET DATA
Current assets Rs m66,96827,610 242.6%   
Current liabilities Rs m40,2118,569 469.3%   
Net working cap to sales %27.151.8 52.4%  
Current ratio x1.73.2 51.7%  
Inventory Days Days8360 138.4%  
Debtors Days Days8127 296.4%  
Net fixed assets Rs m33,3221,057 3,152.8%   
Share capital Rs m282213 132.8%   
"Free" reserves Rs m55,77019,873 280.6%   
Net worth Rs m56,05220,086 279.1%   
Long term debt Rs m35,7380-   
Total assets Rs m132,88829,409 451.9%  
Interest coverage x4.4311.6 1.4%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.71.3 59.4%   
Return on assets %9.515.4 61.6%  
Return on equity %16.522.4 73.6%  
Return on capital %17.834.9 51.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m62,998369 17,074.6%   
Fx outflow Rs m22,8594,918 464.8%   
Net fx Rs m40,140-4,549 -882.3%   
CASH FLOW
From Operations Rs m13,2424,991 265.3%  
From Investments Rs m-6,990-2,570 272.0%  
From Financial Activity Rs m-7,387-1,428 517.3%  
Net Cashflow Rs m-2,971993 -299.1%  

Share Holding

Indian Promoters % 48.3 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 6.9 7.9 87.3%  
FIIs % 34.4 0.1 34,400.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 17.1 61.4%  
Shareholders   56,727 18,270 310.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   SANOFI INDIA  TORRENT PHARMA  FRESENIUS KABI ONCO.  CIPLA  GSK PHARMA  

Compare GLENMARK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Economic Growth and Stock Markets: It's Not All Gloom and Doom(Podcast)

In addition to the usual stock market updates of the week, I talk about how RBI's monetary policy decision and slowing economy impacts you and your portfolio of stocks.

Related Views on News

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY19); Net Profit Up 13.1% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 13.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.0% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

More Views on News

Most Popular

Could this Smallcap Be the Next Page Industries?(Profit Hunter)

Nov 27, 2019

A single stock - Coca Cola, made Buffett billions. Here's your chance to break into the crorepati club with a single smallcap stock investment.

How We Made 12.68% in One Overnight Trade(The 5 Minute Wrapup)

Nov 25, 2019

This one trade had my subscribers laughing all the way to the bank.

Growth Stocks or Value Stocks... What Will Make You More Money in this Bull Market?(Profit Hunter)

Nov 28, 2019

Should you invest in growth stocks or value stocks to make strong returns in this market?

Two Trends to Look at as Sensex Crosses 41,000 Levels(Views On News)

Nov 26, 2019

The two trends that are playing out as Sensex touches new record high.

The Best Trading Strategy for Fast Profits

Nov 29, 2019

Vijay and I have decided to team up and bring you a unique offering never seen before in the Indian stock markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Dec 6, 2019 03:31 PM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS